Find in Library
Search millions of books, articles, and more
Indexed Open Access Databases
A cohort study measuring SARS-CoV-2 seroconversion and serial viral testing in university students
oleh: Christine C. Lee, Hannah E. Segaloff, Devlin Cole, Hannah G. Rosenblum, Clint N. Morgan, Tarah Somers, Rodel Desamu-Thorpe, Monique A. Foster, Dustin Currie, Jeanne Ruff, David Payne, Thomas J. Whyte, Glen R. Abedi, John Paul Bigouette, Juliana Kahrs, Kimberly Langolf, Patrick Remington, Alana Sterkel, Patrick Kelly, Ryan P. Westergaard, Allen C. Bateman, Christopher H. Hsu, Jacqueline E. Tate, Hannah L. Kirking
Format: | Article |
---|---|
Diterbitkan: | BMC 2022-03-01 |
Deskripsi
Abstract Background To improve understanding of the antibody response to SARS-CoV-2 infection, we examined seroprevalence, incidence of infection, and seroconversion among a cohort of young adults living on university campuses during the fall of 2020. Methods At the beginning (semester start) and end (semester end) of an 11-week period, serum collected from 107 students was tested using the qualitative Abbott Architect SARS-CoV-2 IgG and AdviseDx SARS-CoV-2 IgG II assays. Results were matched to interim weekly surveillance viral testing and symptom data. Results With the SARS-CoV-2 IgG assay, 15 (14.0%) students were seropositive at semester start; 29 (27.1%) students were seropositive at semester end; 10 (9.3%) were seropositive at both times. With the AdviseDx SARS-CoV-2 IgG II assay, 17 (16.3%) students were seropositive at semester start, 37 (35.6%) were seropositive at semester end, and 16 (15.3%) were seropositive at both times. Overall, 23 students (21.5%) had positive viral tests during the semester. Infection was identified by serial testing in a large majority of individuals who seroconverted using both assays. Those seropositive at semester end more frequently reported symptomatic infections (56.5%) than asymptomatic infections (30.4%). Conclusion Differences between antibody targets were observed, with more declines in antibody index values below the threshold of positivity with the anti-nucleocapsid assay compared to the anti-spike assay. Serology testing, combined with serial viral testing, can detect seroconversions, and help understand the potential correlates of protection provided by antibodies to SARS-CoV-2.